QCM
KRYS icon

Quantinno Capital Management’s Krystal Biotech KRYS Stock Holding History

Quantinno Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
4,018
+847
+27% +$253K ﹤0.01% 2224
2026
Q1 		$819K Buy
3,171
+267
+9% +$71K ﹤0.01% 2332
2025
Q4 		$716K Buy
2,904
+742
+34% +$156K ﹤0.01% 2064
2025
Q3 		$382K Buy
+2,162
New +$324K ﹤0.01% 2252

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quantinno Capital Management's KRYS Position: Q2 2026 in Review

Quantinno Capital Management increased its Krystal Biotech (KRYS) stake by 27% in Q2 2026, buying an estimated $253K and bringing the position to 4,018 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2224.

Quantinno Capital Management first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Quantinno Capital Management held 4,018 shares of Krystal Biotech worth $1.49M as of Q2 2026.
  • Quantinno Capital Management bought 847 Krystal Biotech shares in Q2 2026, an estimated $253K.
  • Krystal Biotech made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2224 holding.
  • Quantinno Capital Management first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.